Global Atherosclerosis Market

Atherosclerosis Comprehensive Study by Treatment (Medication, Catheter-based Procedures (Balloon angioplasty, Atherectomy), Surgery (Endarterectomy, Arterioplasty, Bypass)), Distribution Channel (Hospital Pharmacies, Drug Stores, Retail Pharmacies, Clinics) Players and Region - Global Market Outlook to 2028

Atherosclerosis Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Atherosclerosis Market Overview:
Atherosclerosis is when the blood vessels become hard due to buildup of plaque. The artery becomes narrow and harden because of the buildup plaque this limits the flow of oxygen-rich blood to your organs and other parts of your body. Plaque is made up of cholesterol, fat, calcium, and other elements that are found in the blood. Plague can lead to serious problems, like heart attack, stroke, or even death.

AttributesDetails
Study Period2018-2028
Base Year2022
Forecast Period2023-2028
Historical Period2018-2022
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Influencing Trend:
Advanced Diagnostic Techniques Employed For Diagnosis of Atherosclerosis

Market Growth Drivers:
Increasing Number of Patients Suffering From Coronary Heart Disease and Rising Number of Aging Population

Challenges:
high cost associated with the treatment

Restraints:
Adequate Definitive Treatment and Limited Availability of Drugs

Opportunities:
Rising Emphasis on Identification of New Drug for Atherosclerosis

Competitive Landscape:

Some of the key players profiled in the report are AstraZeneca Plc (United Kingdom), Bayer AG (Germany), Merck and Co. Inc. (United States), Novartis AG (Switzerland), Sanofi (France), Anthera Pharmaceuticals (United States), Taxus Cardium (United States), F. Hoffmann-La Roche Ltd. (Switzerland), GlaxoSmithKline plc. (United Kingdom), Ionis Pharmaceuticals, Inc. (United States), Johnson and Johnson (United States) and Merck & Co., Inc. (United States). Analyst at AMA Research see European Players to retain maximum share of Global Atherosclerosis market by 2028. Considering Market by Treatment, the sub-segment i.e. Medication will boost the Atherosclerosis market. Considering Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacies will boost the Atherosclerosis market.

Latest Market Insights:
On December 17, 2019 - Roche and Spark Therapeutics, Inc. (“Spark”) today announced the completion of the acquisition. Roche and Spark will be able to significantly improve the lives of patients through innovative gene therapies. This acquisition supports Roche long-lasting commitment to bringing transformational therapies and innovative approaches to people around the world with serious diseases.

In June 2022, Novartis reported that the probability that continuous Kesimpta® (ofatumumab) treatment will achieve no evidence of disease activity (NEDA-3) was switched from teriflunomide. The findings were presented at the annual meeting of the European Society for Neuroscience (EAN), which will be held virtually in Vienna, Austria, June 25-28, 2022.

What Can be Explored with the Atherosclerosis Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Atherosclerosis Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Atherosclerosis
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Atherosclerosis market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Atherosclerosis market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Service Providers of Atherosclerosis, Pharmaceutical Industry, Regulatory Bodies and Governmental Bodies.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Treatment
  • Medication
  • Catheter-based Procedures [Balloon angioplasty, Atherectomy]
  • Surgery [Endarterectomy, Arterioplasty, Bypass]

By Distribution Channel
  • Hospital Pharmacies
  • Drug Stores
  • Retail Pharmacies
  • Clinics

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Number of Patients Suffering From Coronary Heart Disease
      • 3.2.2. Rising Number of Aging Population
    • 3.3. Market Challenges
      • 3.3.1. High cost associated with the treatment
    • 3.4. Market Trends
      • 3.4.1. Advanced Diagnostic Techniques Employed For Diagnosis of Atherosclerosis
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Atherosclerosis, by Treatment, Distribution Channel and Region (value and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Atherosclerosis (Value)
      • 5.2.1. Global Atherosclerosis by: Treatment (Value)
        • 5.2.1.1. Medication
        • 5.2.1.2. Catheter-based Procedures [Balloon angioplasty, Atherectomy]
        • 5.2.1.3. Surgery [Endarterectomy, Arterioplasty, Bypass]
      • 5.2.2. Global Atherosclerosis by: Distribution Channel (Value)
        • 5.2.2.1. Hospital Pharmacies
        • 5.2.2.2. Drug Stores
        • 5.2.2.3. Retail Pharmacies
        • 5.2.2.4. Clinics
      • 5.2.3. Global Atherosclerosis Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Atherosclerosis (Price)
  • 6. Atherosclerosis: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AstraZeneca Plc (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bayer AG (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Merck and Co. Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Novartis AG (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Sanofi (France)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Anthera Pharmaceuticals (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Taxus Cardium (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. F. Hoffmann-La Roche Ltd. (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. GlaxoSmithKline plc. (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Ionis Pharmaceuticals, Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Johnson and Johnson (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Merck & Co., Inc. (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Atherosclerosis Sale, by Treatment, Distribution Channel and Region (value and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Atherosclerosis (Value)
      • 7.2.1. Global Atherosclerosis by: Treatment (Value)
        • 7.2.1.1. Medication
        • 7.2.1.2. Catheter-based Procedures [Balloon angioplasty, Atherectomy]
        • 7.2.1.3. Surgery [Endarterectomy, Arterioplasty, Bypass]
      • 7.2.2. Global Atherosclerosis by: Distribution Channel (Value)
        • 7.2.2.1. Hospital Pharmacies
        • 7.2.2.2. Drug Stores
        • 7.2.2.3. Retail Pharmacies
        • 7.2.2.4. Clinics
      • 7.2.3. Global Atherosclerosis Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Atherosclerosis (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Atherosclerosis: by Treatment(USD Million)
  • Table 2. Atherosclerosis Medication , by Region USD Million (2017-2022)
  • Table 3. Atherosclerosis Catheter-based Procedures [Balloon angioplasty, Atherectomy] , by Region USD Million (2017-2022)
  • Table 4. Atherosclerosis Surgery [Endarterectomy, Arterioplasty, Bypass] , by Region USD Million (2017-2022)
  • Table 5. Atherosclerosis: by Distribution Channel(USD Million)
  • Table 6. Atherosclerosis Hospital Pharmacies , by Region USD Million (2017-2022)
  • Table 7. Atherosclerosis Drug Stores , by Region USD Million (2017-2022)
  • Table 8. Atherosclerosis Retail Pharmacies , by Region USD Million (2017-2022)
  • Table 9. Atherosclerosis Clinics , by Region USD Million (2017-2022)
  • Table 10. South America Atherosclerosis, by Country USD Million (2017-2022)
  • Table 11. South America Atherosclerosis, by Treatment USD Million (2017-2022)
  • Table 12. South America Atherosclerosis, by Distribution Channel USD Million (2017-2022)
  • Table 13. Brazil Atherosclerosis, by Treatment USD Million (2017-2022)
  • Table 14. Brazil Atherosclerosis, by Distribution Channel USD Million (2017-2022)
  • Table 15. Argentina Atherosclerosis, by Treatment USD Million (2017-2022)
  • Table 16. Argentina Atherosclerosis, by Distribution Channel USD Million (2017-2022)
  • Table 17. Rest of South America Atherosclerosis, by Treatment USD Million (2017-2022)
  • Table 18. Rest of South America Atherosclerosis, by Distribution Channel USD Million (2017-2022)
  • Table 19. Asia Pacific Atherosclerosis, by Country USD Million (2017-2022)
  • Table 20. Asia Pacific Atherosclerosis, by Treatment USD Million (2017-2022)
  • Table 21. Asia Pacific Atherosclerosis, by Distribution Channel USD Million (2017-2022)
  • Table 22. China Atherosclerosis, by Treatment USD Million (2017-2022)
  • Table 23. China Atherosclerosis, by Distribution Channel USD Million (2017-2022)
  • Table 24. Japan Atherosclerosis, by Treatment USD Million (2017-2022)
  • Table 25. Japan Atherosclerosis, by Distribution Channel USD Million (2017-2022)
  • Table 26. India Atherosclerosis, by Treatment USD Million (2017-2022)
  • Table 27. India Atherosclerosis, by Distribution Channel USD Million (2017-2022)
  • Table 28. South Korea Atherosclerosis, by Treatment USD Million (2017-2022)
  • Table 29. South Korea Atherosclerosis, by Distribution Channel USD Million (2017-2022)
  • Table 30. Taiwan Atherosclerosis, by Treatment USD Million (2017-2022)
  • Table 31. Taiwan Atherosclerosis, by Distribution Channel USD Million (2017-2022)
  • Table 32. Australia Atherosclerosis, by Treatment USD Million (2017-2022)
  • Table 33. Australia Atherosclerosis, by Distribution Channel USD Million (2017-2022)
  • Table 34. Rest of Asia-Pacific Atherosclerosis, by Treatment USD Million (2017-2022)
  • Table 35. Rest of Asia-Pacific Atherosclerosis, by Distribution Channel USD Million (2017-2022)
  • Table 36. Europe Atherosclerosis, by Country USD Million (2017-2022)
  • Table 37. Europe Atherosclerosis, by Treatment USD Million (2017-2022)
  • Table 38. Europe Atherosclerosis, by Distribution Channel USD Million (2017-2022)
  • Table 39. Germany Atherosclerosis, by Treatment USD Million (2017-2022)
  • Table 40. Germany Atherosclerosis, by Distribution Channel USD Million (2017-2022)
  • Table 41. France Atherosclerosis, by Treatment USD Million (2017-2022)
  • Table 42. France Atherosclerosis, by Distribution Channel USD Million (2017-2022)
  • Table 43. Italy Atherosclerosis, by Treatment USD Million (2017-2022)
  • Table 44. Italy Atherosclerosis, by Distribution Channel USD Million (2017-2022)
  • Table 45. United Kingdom Atherosclerosis, by Treatment USD Million (2017-2022)
  • Table 46. United Kingdom Atherosclerosis, by Distribution Channel USD Million (2017-2022)
  • Table 47. Netherlands Atherosclerosis, by Treatment USD Million (2017-2022)
  • Table 48. Netherlands Atherosclerosis, by Distribution Channel USD Million (2017-2022)
  • Table 49. Rest of Europe Atherosclerosis, by Treatment USD Million (2017-2022)
  • Table 50. Rest of Europe Atherosclerosis, by Distribution Channel USD Million (2017-2022)
  • Table 51. MEA Atherosclerosis, by Country USD Million (2017-2022)
  • Table 52. MEA Atherosclerosis, by Treatment USD Million (2017-2022)
  • Table 53. MEA Atherosclerosis, by Distribution Channel USD Million (2017-2022)
  • Table 54. Middle East Atherosclerosis, by Treatment USD Million (2017-2022)
  • Table 55. Middle East Atherosclerosis, by Distribution Channel USD Million (2017-2022)
  • Table 56. Africa Atherosclerosis, by Treatment USD Million (2017-2022)
  • Table 57. Africa Atherosclerosis, by Distribution Channel USD Million (2017-2022)
  • Table 58. North America Atherosclerosis, by Country USD Million (2017-2022)
  • Table 59. North America Atherosclerosis, by Treatment USD Million (2017-2022)
  • Table 60. North America Atherosclerosis, by Distribution Channel USD Million (2017-2022)
  • Table 61. United States Atherosclerosis, by Treatment USD Million (2017-2022)
  • Table 62. United States Atherosclerosis, by Distribution Channel USD Million (2017-2022)
  • Table 63. Canada Atherosclerosis, by Treatment USD Million (2017-2022)
  • Table 64. Canada Atherosclerosis, by Distribution Channel USD Million (2017-2022)
  • Table 65. Mexico Atherosclerosis, by Treatment USD Million (2017-2022)
  • Table 66. Mexico Atherosclerosis, by Distribution Channel USD Million (2017-2022)
  • Table 67. Company Basic Information, Sales Area and Its Competitors
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Company Basic Information, Sales Area and Its Competitors
  • Table 78. Company Basic Information, Sales Area and Its Competitors
  • Table 79. Atherosclerosis: by Treatment(USD Million)
  • Table 80. Atherosclerosis Medication , by Region USD Million (2023-2028)
  • Table 81. Atherosclerosis Catheter-based Procedures [Balloon angioplasty, Atherectomy] , by Region USD Million (2023-2028)
  • Table 82. Atherosclerosis Surgery [Endarterectomy, Arterioplasty, Bypass] , by Region USD Million (2023-2028)
  • Table 83. Atherosclerosis: by Distribution Channel(USD Million)
  • Table 84. Atherosclerosis Hospital Pharmacies , by Region USD Million (2023-2028)
  • Table 85. Atherosclerosis Drug Stores , by Region USD Million (2023-2028)
  • Table 86. Atherosclerosis Retail Pharmacies , by Region USD Million (2023-2028)
  • Table 87. Atherosclerosis Clinics , by Region USD Million (2023-2028)
  • Table 88. South America Atherosclerosis, by Country USD Million (2023-2028)
  • Table 89. South America Atherosclerosis, by Treatment USD Million (2023-2028)
  • Table 90. South America Atherosclerosis, by Distribution Channel USD Million (2023-2028)
  • Table 91. Brazil Atherosclerosis, by Treatment USD Million (2023-2028)
  • Table 92. Brazil Atherosclerosis, by Distribution Channel USD Million (2023-2028)
  • Table 93. Argentina Atherosclerosis, by Treatment USD Million (2023-2028)
  • Table 94. Argentina Atherosclerosis, by Distribution Channel USD Million (2023-2028)
  • Table 95. Rest of South America Atherosclerosis, by Treatment USD Million (2023-2028)
  • Table 96. Rest of South America Atherosclerosis, by Distribution Channel USD Million (2023-2028)
  • Table 97. Asia Pacific Atherosclerosis, by Country USD Million (2023-2028)
  • Table 98. Asia Pacific Atherosclerosis, by Treatment USD Million (2023-2028)
  • Table 99. Asia Pacific Atherosclerosis, by Distribution Channel USD Million (2023-2028)
  • Table 100. China Atherosclerosis, by Treatment USD Million (2023-2028)
  • Table 101. China Atherosclerosis, by Distribution Channel USD Million (2023-2028)
  • Table 102. Japan Atherosclerosis, by Treatment USD Million (2023-2028)
  • Table 103. Japan Atherosclerosis, by Distribution Channel USD Million (2023-2028)
  • Table 104. India Atherosclerosis, by Treatment USD Million (2023-2028)
  • Table 105. India Atherosclerosis, by Distribution Channel USD Million (2023-2028)
  • Table 106. South Korea Atherosclerosis, by Treatment USD Million (2023-2028)
  • Table 107. South Korea Atherosclerosis, by Distribution Channel USD Million (2023-2028)
  • Table 108. Taiwan Atherosclerosis, by Treatment USD Million (2023-2028)
  • Table 109. Taiwan Atherosclerosis, by Distribution Channel USD Million (2023-2028)
  • Table 110. Australia Atherosclerosis, by Treatment USD Million (2023-2028)
  • Table 111. Australia Atherosclerosis, by Distribution Channel USD Million (2023-2028)
  • Table 112. Rest of Asia-Pacific Atherosclerosis, by Treatment USD Million (2023-2028)
  • Table 113. Rest of Asia-Pacific Atherosclerosis, by Distribution Channel USD Million (2023-2028)
  • Table 114. Europe Atherosclerosis, by Country USD Million (2023-2028)
  • Table 115. Europe Atherosclerosis, by Treatment USD Million (2023-2028)
  • Table 116. Europe Atherosclerosis, by Distribution Channel USD Million (2023-2028)
  • Table 117. Germany Atherosclerosis, by Treatment USD Million (2023-2028)
  • Table 118. Germany Atherosclerosis, by Distribution Channel USD Million (2023-2028)
  • Table 119. France Atherosclerosis, by Treatment USD Million (2023-2028)
  • Table 120. France Atherosclerosis, by Distribution Channel USD Million (2023-2028)
  • Table 121. Italy Atherosclerosis, by Treatment USD Million (2023-2028)
  • Table 122. Italy Atherosclerosis, by Distribution Channel USD Million (2023-2028)
  • Table 123. United Kingdom Atherosclerosis, by Treatment USD Million (2023-2028)
  • Table 124. United Kingdom Atherosclerosis, by Distribution Channel USD Million (2023-2028)
  • Table 125. Netherlands Atherosclerosis, by Treatment USD Million (2023-2028)
  • Table 126. Netherlands Atherosclerosis, by Distribution Channel USD Million (2023-2028)
  • Table 127. Rest of Europe Atherosclerosis, by Treatment USD Million (2023-2028)
  • Table 128. Rest of Europe Atherosclerosis, by Distribution Channel USD Million (2023-2028)
  • Table 129. MEA Atherosclerosis, by Country USD Million (2023-2028)
  • Table 130. MEA Atherosclerosis, by Treatment USD Million (2023-2028)
  • Table 131. MEA Atherosclerosis, by Distribution Channel USD Million (2023-2028)
  • Table 132. Middle East Atherosclerosis, by Treatment USD Million (2023-2028)
  • Table 133. Middle East Atherosclerosis, by Distribution Channel USD Million (2023-2028)
  • Table 134. Africa Atherosclerosis, by Treatment USD Million (2023-2028)
  • Table 135. Africa Atherosclerosis, by Distribution Channel USD Million (2023-2028)
  • Table 136. North America Atherosclerosis, by Country USD Million (2023-2028)
  • Table 137. North America Atherosclerosis, by Treatment USD Million (2023-2028)
  • Table 138. North America Atherosclerosis, by Distribution Channel USD Million (2023-2028)
  • Table 139. United States Atherosclerosis, by Treatment USD Million (2023-2028)
  • Table 140. United States Atherosclerosis, by Distribution Channel USD Million (2023-2028)
  • Table 141. Canada Atherosclerosis, by Treatment USD Million (2023-2028)
  • Table 142. Canada Atherosclerosis, by Distribution Channel USD Million (2023-2028)
  • Table 143. Mexico Atherosclerosis, by Treatment USD Million (2023-2028)
  • Table 144. Mexico Atherosclerosis, by Distribution Channel USD Million (2023-2028)
  • Table 145. Research Programs/Design for This Report
  • Table 146. Key Data Information from Secondary Sources
  • Table 147. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Atherosclerosis: by Treatment USD Million (2017-2022)
  • Figure 5. Global Atherosclerosis: by Distribution Channel USD Million (2017-2022)
  • Figure 6. South America Atherosclerosis Share (%), by Country
  • Figure 7. Asia Pacific Atherosclerosis Share (%), by Country
  • Figure 8. Europe Atherosclerosis Share (%), by Country
  • Figure 9. MEA Atherosclerosis Share (%), by Country
  • Figure 10. North America Atherosclerosis Share (%), by Country
  • Figure 11. Global Atherosclerosis share by Players 2022 (%)
  • Figure 12. Global Atherosclerosis share by Players (Top 3) 2022(%)
  • Figure 13. Global Atherosclerosis share by Players (Top 5) 2022(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. AstraZeneca Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 16. AstraZeneca Plc (United Kingdom) Revenue: by Geography 2022
  • Figure 17. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 18. Bayer AG (Germany) Revenue: by Geography 2022
  • Figure 19. Merck and Co. Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Merck and Co. Inc. (United States) Revenue: by Geography 2022
  • Figure 21. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 22. Novartis AG (Switzerland) Revenue: by Geography 2022
  • Figure 23. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 24. Sanofi (France) Revenue: by Geography 2022
  • Figure 25. Anthera Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 26. Anthera Pharmaceuticals (United States) Revenue: by Geography 2022
  • Figure 27. Taxus Cardium (United States) Revenue, Net Income and Gross profit
  • Figure 28. Taxus Cardium (United States) Revenue: by Geography 2022
  • Figure 29. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 30. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2022
  • Figure 31. GlaxoSmithKline plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 32. GlaxoSmithKline plc. (United Kingdom) Revenue: by Geography 2022
  • Figure 33. Ionis Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Ionis Pharmaceuticals, Inc. (United States) Revenue: by Geography 2022
  • Figure 35. Johnson and Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 36. Johnson and Johnson (United States) Revenue: by Geography 2022
  • Figure 37. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 38. Merck & Co., Inc. (United States) Revenue: by Geography 2022
  • Figure 39. Global Atherosclerosis: by Treatment USD Million (2023-2028)
  • Figure 40. Global Atherosclerosis: by Distribution Channel USD Million (2023-2028)
  • Figure 41. South America Atherosclerosis Share (%), by Country
  • Figure 42. Asia Pacific Atherosclerosis Share (%), by Country
  • Figure 43. Europe Atherosclerosis Share (%), by Country
  • Figure 44. MEA Atherosclerosis Share (%), by Country
  • Figure 45. North America Atherosclerosis Share (%), by Country
List of companies from research coverage that are profiled in the study
  • AstraZeneca Plc (United Kingdom)
  • Bayer AG (Germany)
  • Merck and Co. Inc. (United States)
  • Novartis AG (Switzerland)
  • Sanofi (France)
  • Anthera Pharmaceuticals (United States)
  • Taxus Cardium (United States)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • GlaxoSmithKline plc. (United Kingdom)
  • Ionis Pharmaceuticals, Inc. (United States)
  • Johnson and Johnson (United States)
  • Merck & Co., Inc. (United States)
Select User Access Type

Key Highlights of Report


May 2023 216 Pages 86 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Atherosclerosis Market Quantitative research analysis
Global Atherosclerosis Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Atherosclerosis market are AstraZeneca Plc (United Kingdom), Bayer AG (Germany), Merck and Co. Inc. (United States), Novartis AG (Switzerland), Sanofi (France), Anthera Pharmaceuticals (United States), Taxus Cardium (United States), F. Hoffmann-La Roche Ltd. (Switzerland), GlaxoSmithKline plc. (United Kingdom), Ionis Pharmaceuticals, Inc. (United States), Johnson and Johnson (United States) and Merck & Co., Inc. (United States), to name a few.
"Advanced Diagnostic Techniques Employed For Diagnosis of Atherosclerosis" is seen as one of major influencing trends for Atherosclerosis Market during projected period 2022-2028.

Know More About Global Atherosclerosis Market Report?

Have a Query? Click Here

Other Related Reports

Blood Coagulants Comprehensive Study by Type (Aprotinin, Tranexamic Acid (TXA), Epsilon-Aminocaproic acid, Aminomethylbenzoic acid, Other), Application (Hemophilia, Surgery (Post-Operative Care), Men...
$ 3750
Dural Repair Comprehensive Study by Type (Sheets, Patches, Plugs, Glues, Others), Application (Neurosurgery, Spine Surgery, Maxillofacial Surgery, Others), End Users (Hospitals, Clinics, Research Ins...
$ 3500
Dysautonomia Comprehensive Study by Type (Neurocardiogenic Syncope, Postural Orthostatic Tachycardia Syndrome, Multiple System Atrophy, Autonomic Dysreflexia, Baroreflex Failure, Others), Treatment (...
$ 3750
Coronavirus Comprehensive Study by Type (Middle East Respiratory Syndrome (MERS) {MER-CoV}, Severe Acute Respiratory Syndrome (SARS) {SAR-CoV}), Application (Hospitals, Research Laboratories, Clinics...
$ 3650
Hunter Syndrome Treatment Comprehensive Study by Type (Enzyme Replacement Therapy (ERT), Hematopoietic Stem Cell Transplant (HSCT), Others), End-user (Life Science Companies, Research Institutes, Hos...
$ 3500
Acute Wound Care Comprehensive Study by Type (Infection Management, Exudate Management,, Active Wound Care, Therapy Devices), Wounds (Surgical Wounds, Traumatic Wounds), End-user (Long- Term Care Fac...
$ 3450